Merck Braces for Study on Medicines Worth $4 Billion a Year

Merck & Co.’s pills Zetia and Vytorin generated more than $21 billion for the company since they were introduced more than a decade ago. Next week, doctors will find out if they actually save lives in addition to lowering cholesterol.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.